Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balsm Alofoq Medical Co's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 9.32.
Balsm Alofoq Medical Co's Days Inventory for the
six
months ended in Dec. 2025 was 88.02.
Balsm Alofoq Medical Co's Days Payable for the
six
months ended in Dec. 2025 was 15.2.
Therefore, Balsm Alofoq Medical Co's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 82.14.
Balsm Alofoq Medical Co (SAU:9620) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Balsm Alofoq Medical Co Cash Conversion Cycle Related Terms
Balsm Alofoq Medical Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Balsm Alofoq Medical Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balsm Alofoq Medical Co Cash Conversion Cycle Chart
Balsm Alofoq Medical Co Annual Data
Trend
Dec23
Dec24
Dec25
Cash Conversion Cycle
49.03
47.02
78.31
Balsm Alofoq Medical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Cash Conversion Cycle
0.00
48.13
46.19
69.73
82.14
SAU:9620 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Balsm Alofoq Medical Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balsm Alofoq Medical Co Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Balsm Alofoq Medical Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Balsm Alofoq Medical Co's Cash Conversion Cycle falls into.
Balsm Alofoq Medical Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Balsm Alofoq Medical Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balsm Alofoq Medical Co (SAU:9620) has a Cash Conversion Cycle of 82.14 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Balsm Alofoq Medical Co and its competitors.
Is Balsm Alofoq Medical Co's Cash Conversion Cycle too high?
Balsm Alofoq Medical Co's current Cash Conversion Cycle is 82.14. The Medical Devices & Instruments industry median Cash Conversion Cycle is 159.01. Balsm Alofoq Medical Co's value of 82.14 is 48.3% below this industry median. Overall, Balsm Alofoq Medical Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Balsm Alofoq Medical Co's Cash Conversion Cycle compare to ABT and SYK?
Balsm Alofoq Medical Co's Cash Conversion Cycle of 82.14 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 159.01. Balsm Alofoq Medical Co's value of 82.14 is 48.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 159.01, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balsm Alofoq Medical Co's current Cash Conversion Cycle of 82.14 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Balsm Alofoq Medical Co and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 159.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balsm Alofoq Medical Co's current Cash Conversion Cycle is 82.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balsm Alofoq Medical Co stock overvalued right now?
Balsm Alofoq Medical Co (SAU:9620) has a current Cash Conversion Cycle of 82.14. The current Cash Conversion Cycle is 82.14 and 48.3% below the Medical Devices & Instruments industry median of 159.01. Balsm Alofoq Medical Co's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Balsm Alofoq Medical Co (SAU:9620), the current Cash Conversion Cycle is 82.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Balsm Alofoq Medical Co operates in the medical sector. Its activities include medical services, specialized clinics and medical complexes, medical operations, and the import and supply of medical devices and supplies to all regions of the Kingdom of Saudi Arabia.
24GF Score
Get the complete analysis for SAU:9620
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9620 has been successfully added to your 
